FindTrial
Sign In

Improving cervical cancer treatment with image guided brachytherapy

Assessment of treatment outcomes using Image Guided Adaptive Brachytherapy (IGABT) for cervical cancer - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/086522
Enrollment
49
Registered
2025-05-07
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C530- Malignant neoplasm of endocervix Health Condition 2: C531- Malignant neoplasm of exocervix Health Condition 3: C538- Malignant neoplasm of overlappingsites of cervix uteri Health Condition 4: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: NIL: NIL

Sponsors

Dr Rahul
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Histologically confirmed diagnosis of cervical cancer (FIGO stages IB to IVA). Patients planned for chemoradiotherapy followed by IGABT. Patients who consent to imaging-based brachytherapy (MRI or CT). Age: 18 years and above with ECOG performance status ECOG less than or equal to 2.

Exclusion criteria

Exclusion criteria: History of prior pelvic irradiation Pregnancy and lactation Any contraindication for CT and MRI imaging Poor performance status(ECOG more than 2) Patients with coexisting malignancies

Design outcomes

Primary

MeasureTime frame
Assessment of tumor outcomes using image guided brachytherapyTimepoint: Assessment at 1st month, 3rd month and 6th months—

Secondary

MeasureTime frame
To assess the impact of IGABT on treatment related toxicity & patient quality of lifeTimepoint: at 1 month 3 month & 6 month—

Countries

India

Contacts

Public ContactDr A Kesava Ramgopal

AIIMS Mangalagiri

kesav.rt@aiimsmangalagiri.edu.in9491331850

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026